Himension Capital Singapore PTE. LTD. purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,481 shares of the company’s stock, valued at approximately $260,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Stifel Financial Corp lifted its position in Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after acquiring an additional 271 shares during the last quarter. D.A. Davidson & CO. grew its position in shares of Twist Bioscience by 1.2% in the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after purchasing an additional 305 shares during the last quarter. CWM LLC grew its position in shares of Twist Bioscience by 9.4% in the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after purchasing an additional 407 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after purchasing an additional 453 shares during the period.
Insider Transactions at Twist Bioscience
In related news, insider Dennis Cho sold 14,205 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the transaction, the insider directly owned 105,141 shares in the company, valued at $9,436,404.75. This represents a 11.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. The trade was a 2.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 50,711 shares of company stock valued at $4,230,246. 3.08% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
View Our Latest Report on Twist Bioscience
Twist Bioscience Stock Down 1.7%
NASDAQ TWST opened at $94.21 on Thursday. The business has a fifty day moving average price of $79.96 and a two-hundred day moving average price of $59.47. The stock has a market capitalization of $5.87 billion, a PE ratio of -70.83 and a beta of 2.11. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $105.47. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. During the same quarter in the previous year, the business posted ($0.66) EPS. The company’s revenue for the quarter was up 19.3% on a year-over-year basis. Equities analysts expect that Twist Bioscience Corporation will post -2.02 earnings per share for the current fiscal year.
About Twist Bioscience
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Stories
- Five stocks we like better than Twist Bioscience
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
